Primary malignant mucosal melanoma of the maxillofacial area
10.5125/jkaoms.2021.47.2.76
- Author:
Hyounmin KIM
1
;
Sanghoon LEE
;
In-Ho CHA
;
Hyung Jun KIM
;
Woong NAM
Author Information
1. Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2021;47(2):76-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments.
Materials and Methods:Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients’ clinical information was reviewed retrospectively.
Results:Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%.
Conclusion:The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection.Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.
